FEB 01, 2017 03:06 PM PST

Diagnosed: Cases of Rare Amnesia Stump Doctors

WRITTEN BY: Xuan Pham

A rare cluster of 14 cases of severe amnesia in Massachusetts has doctors and CDC officials worried and on the hunt for a culprit, which remains unknown.

The mystery began in 2015 when a Boston neurologist, Dr. Jed Barash reported a string of four cases of amnesia with striking similarities. The four cases span over three years. However, all four showed an unusual mark on their MRI scans: their hippocampi seemed to have lost blood flow. The ischemia, as diagnosed by doctors, did not seem to stem from trauma or to be stroke-related.

The hippocampus is a brain region essential for memory. Small and unassuming, the hippocampus plays a big role in transferring short- to long-term memory. In Alzheimer's and dementia patients who suffer from memory loss and disorientation, the hippocampus is usually one of the first regions to show damages. Patients who suffer trauma to the hippocampus have also reported experiences of anterograde amnesia - the inability to form new memories.

Upon further investigation, doctors noted another similarity. All four patients either tested positive for opioids or had a history of substance abuse.

Without knowing the scope of things, Barash contacted Dr. Alfred DeMaria Jr, the state epidemiologist for the Massachusetts Department of Public Health. "We couldn't really address what was causing this," said Dr. Alfred DeMaria.

To investigate whether these cases were isolated or if something more insidious was happening, the Department of Health issued a statewide alert. Doctors soon reported another 10 cases with similar characteristics: young patients between 19 and 52 years old, prior drug use, “striking anterograde amnesia,” and the telltale MRI mark on the hippocampi.

Because none of the cases were ongoing, researchers have to play detective based on medical history. "All we had was the medical records," DeMaria said. "We couldn't go back (in time)." Of note, 12 patients had opioid abuse, while others had used marijuana, cocaine, and amphetamines.

The cases point to drug abuse as a likely smoking gun for the amnesia. However, researchers are cautious to make such a connection until they identify more cases and establish a strong pattern.

Indeed, DeMaria said this cluster of amnesia cases may "[represent] an emerging syndrome related to substance use or other causes. Maybe nobody was looking for this," DeMaria said. "Maybe this isn't new. Maybe it was happening all along."

Additional sources: Live Science, CNN

About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
APR 21, 2018
Cardiology
APR 21, 2018
Scientists Recommend Exercise After A Heart Attack
Doctors recommend regular physical activity to reduce the risk of a heart attack, but the same advice applies even after a person has a heart attack. A new...
APR 25, 2018
Clinical & Molecular DX
APR 25, 2018
Why is dementia going unnoticed in hospitals?
A study in the UK showed that while the rate of diagnosis for dementia is improving, more than a third of all dementia patients still go undiagnosed. The n...
MAY 24, 2018
Neuroscience
MAY 24, 2018
Can Brain Fold Patterns Predict Psychosis?
While it's a famous slogan and not meant to be taken verbatim, in neuroscience, it's often true that "Image is everything." A recent stud...
MAY 29, 2018
Microbiology
MAY 29, 2018
Environmental Factors Drive Belly Fat Buildup
Abdominal fat is a major risk factor for disease. New work could help find those at risk for increased belly fat, and help reverse that trend....
JUN 02, 2018
Immunology
JUN 02, 2018
New Test Predicts Lupus Onset
Based on several different factors, scientists have a new risk index for predicting who will develop lupus. From the Feinstein Institute for Medical Resear...
AUG 22, 2018
Clinical & Molecular DX
AUG 22, 2018
New Clinical Assay Useful For Urothelial Cancer
U.S. Food and Drug Administration (FDA) has now approved a pharmDx assay called ‘Dako PD-L1 IHC 22C3’ by Agilent Technologies Inc. for use in u...
Loading Comments...